An official website of the United States government
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
Trial Status: active
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer.
RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying
cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.
Inclusion Criteria
A man with a diagnosis of prostate cancer that is either:
new (i.e. the diagnosis was made within 1 year of the enrolment visit) or
treated with Androgen Deprivation Therapy for the first time within 6 months prior to the enrolment visit, or
to be treated with Androgen Deprivation Therapy for the first time within 1 month after the enrolment visit
Exclusion Criteria
Patients will be excluded if they fulfill any of the following:
are unwilling to provide consent or
are <45 years of age, or
prostate cancer was found incidentally following cystectomy for bladder cancer
Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:
see a cardiologist every year, or
both take a statin and have systolic blood pressure ≤130mmHg
Additional locations may be listed on ClinicalTrials.gov for NCT03127631.
Locations matching your search criteria
United States
Kansas
Kansas City
University of Kansas Cancer Center
Status: Active
Name Not Available
Pennsylvania
Philadelphia
University of Pennsylvania/Abramson Cancer Center
Status: Active
Name Not Available
Texas
Dallas
UT Southwestern/Simmons Cancer Center-Dallas
Status: Active
Name Not Available
RADICAL PC describes two prospective studies, one of which is embedded in the other.
RADICAL PC1 is a prospective cohort study of men within one year of their first diagnosis
of prostate cancer, or treated with Androgen Deprivation Therapy for the first time
within 6 months prior to enrollment visit, or to be treated with Androgen Deprivation
Therapy for the first time within one month after the enrollment visit. Its goal will be
to identify factors associated with the development of cardiovascular disease among men
with prostate cancer, with a particular focus on Androgen Deprivation Therapy. RADICAL
PC2 is a randomized, controlled trial embedded in RADICAL PC1. RADICAL PC2 will test a
systematic approach to modifying cardiovascular and lifestyle risk factors in men within
one year of their first diagnosis of prostate cancer, or treated with Androgen
Deprivation Therapy for the first time within 6 months prior to enrollment visit, or to
be treated with Androgen Deprivation Therapy for the first time within one month after
the enrollment visit.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationMcMaster Children's Hospital at Hamilton Health Sciences
